Anemoside B4 protects against *Klebsiella pneumoniae*- and influenza virus FM1-induced pneumonia via the TLR4/Myd88 signaling pathway in mice

**CURRENT STATUS:** Under Review

Jia He, Renyikun Yuan, Xiaolan Cui, Yushun Cui, Shan Han, Qin-Qin Wang, Yangling Chen, Liting Huang, Shilin Yang, Qiongming Xu, Yonghui Zhao, Hongwei Gao

Jia He  
GuangXi University of Chinese Medicine

Renyikun Yuan  
Jiangxi University of Traditional Chinese Medicine

Xiaolan Cui  
China Academy of Chinese Medical Sciences

Yushun Cui  
Jiangxi University of Traditional Chinese Medicine

Shan Han  
GuangXi University of Chinese Medicine

Qin-Qin Wang  
GuangXi University of Chinese Medicine

Yangling Chen  
GuangXi University of Chinese Medicine

Liting Huang  
GuangXi University of Chinese Medicine

Shilin Yang  
GuangXi University of Chinese Medicine

Qiongming Xu  
GuangXi University of Chinese Medicine

Yonghui Zhao  
Qingdao University

Hongwei Gao  
GuangXi University of Chinese Medicine

✉ gaohongwei06@126.com  
Corresponding Author  
ORCID: https://orcid.org/0000-0001-9179-750X
Prescreen

10.21203/rs.3.rs-27002/v1

Subject Areas

*Infectious Diseases*

Keywords

*Anemoside B4, pneumonia, Klebsiella pneumoniae, influenza virus FM1, TLR4/Myd88*
Abstract

Background Pneumonia refers to the inflammation of the terminal airway, alveoli and pulmonary interstitium, which can be caused by pathogenic microorganisms, physical and chemical factors, immune damage, and drugs. Anemoside B4, the major ingredient of Pulsatilla chinensis (Bunge) Regel, exhibited anti-inflammatory activity. However, the therapeutic effect of anemoside B4 on pneumonia has not been unraveled. This study aims to investigate that anemoside B4 attenuates the inflammatory responses in Klebsiella pneumonia (KP)- and influenza virus FM1 (FM1)-induced pneumonia mice model.

Methods The network pharmacology and molecular docking assays were employed to predict the targets of anemoside B4’s treatment of pneumonia. Two models (bacterial KP-infected mice and virus FM1-infected mice) were employed in our study. BALB/c mice were divided into six groups: control, model group (KP-induced pneumonia or FM1-induced pneumonia), anemoside B4 (B4)-treated group (2.5, 5, 10 mg/kg), and positive drug group (Ribavirin or Ceftriaxone Sodium Injection). Blood samples were collected for hematology analysis. The effects of B4 on inflammation-associated mediators were investigated by Enzyme-linked immunosorbent assay (ELISA). Proteins expression was quantified by western blotting.

Results The network results indicated that many pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) participated in anemoside B4’s anti-inflammatory activity. The counts of neutrophil (NEU) and white blood cell (WBC), the level of myeloperoxidase (MPO), and the release of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 increased by KP or FM1 infection, which were reversed by anemoside B4. In addition, anemoside B4 significantly suppressed the FM1-induced expression of Toll-like receptor 4 (TLR4), myeloid differential protein-88 (MyD88), and myeloid differentiation protein-2 (MD-2), which were further validated by molecular docking data that anemoside B4 bound to bioactive sites of TLR4. Therefore, anemoside B4 exhibited a significant therapeutic effect on pneumonia via the TLR4/MyD88 pathway.

Conclusion Our findings demonstrated that anemoside B4 attenuates pneumonia via the TLR4/Myd88 signaling pathway, suggesting that anemoside B4 is a promising therapeutic candidate for bacterial-infected or viral-infected pneumonia.

Background

Pneumonia refers to the inflammation of the terminal airway, alveoli and pulmonary interstitium caused by many factors, of which typical symptoms include dry cough, chest pain, fever, and dyspnea [1, 2]. Pneumonia has been one of the main factors affecting people’s health and even life for a long time. With the introduction of antibiotics and vaccines in the 20th century, the survival rate of related patients has been greatly improved [3]. However, pneumonia remains the leading cause of death in developing countries, as well as in elderly, young children and chronically ill patients [4]. Klebsiella pneumoniae is one of the most important opportunistic pathogens and iatrogenic pathogens, which is highly pathogenic to human beings [5]. Due to the abuse of various antimicrobial agents, the multi drug resistance of Klebsiella pneumoniae is widespread, which leads to great trouble for clinical treatment [6, 7]. Influenza virus is the representative of orthomyxoviridae, including human influenza virus and animal influenza virus[8, 9]. Influenza virus infection, whether seasonal or pandemic, often leads to pneumonia, which can cause serious health problems [10, 11]. For the treatment of viral pneumonia, apart from neuraminidase inhibitors and ribavirin, other antiviral drugs showed no significant effect on pneumonia[12]. Specifically, now corona virus COVID-19-induced pneumonia outbreaks world widely, leading to many deaths. As it stands now, there is not effective drugs for the treatment with pneumonia. Therefore, it is urgent to find new and effective drugs for treatment with pneumonia.

Network pharmacology is an emerging discipline that builds and analyzes biological networks based on systems biology to reveal the role of drugs and their mechanisms[13]. By constructing a “component-target-pathway” research network, we can observe how drugs act on multiple targets at the same time, thereby regulating multiple signal pathways, comprehensively reveal their drug efficacy network, and explain their mechanism of
action[14]. This provides a certain guiding significance for our work.

During pneumonia process, white blood cell (WBC) and neutrophil (NEU) counts are always increased [15]. In addition, myeloperoxidase (MPO), an enzyme secreted by leukocytes, is present in myeloid cells, which catalyzes the formation of a variety of active oxidants during the occurrence and development of pneumonia [16]. The role of TLRs in the signaling pathway of inflammation and related diseases is highly valued [17]. When induced by external stimuli such as viruses or bacteria, the adaptor protein myeloid differentiation protein-2 (MD2) directly binds and recognizes stimuli forming discrete complex, and associates non-covalently toll-like receptor 4 (TLR4) to form the final activated heterodimer that in its turn starts the intracellular signal [18]. After that, myeloid differentiation primary response 88 (Myd88) is recruited to TLR4, which then activates downstream pathways and results in the pro-inflammatory cytokine release, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) [19]. This suggests that TLR4/MyD88 signaling pathway may be an effective therapeutic target for many inflammatory diseases.

Traditional Chinese medicine has great potential in the treatment of many inflammatory and immunoregulatory diseases [20, 21]. *Pulsatilla chinensis* (Bunge) Regel, a traditional Chinese herb, has the functions of clearing away heat and detoxification, stopping dysentery and drying dampness, and has a good therapeutic effect on bacteria, virus infection and malignant tumors in clinic [22]. Recent studies have shown that triterpenoid saponins are the main factors affecting the pharmacological activities in this herb. Anemoside B4, one of the main monomer components of *Pulsatilla chinensis* (Bunge) Regel, can inhibit the pathogenesis of acute kidney injury caused by cisplatin and improve renal function, which protective effects may be associated with its anti-inflammatory activities [23]. However, there are no papers involved in the therapeutic effect of B4 on pneumonia. In the present study, we used *Klebsiella pneumoniae* or influenza virus FM1-induced pneumonia model to investigate the anti-inflammatory effects and mechanisms of anemoside B4 in vivo.

### Methods

Reagents and Chemicals *Klebsiella pneumoniae* (BNCC-102997) was purchased from Beijing Beina Chuanglian Biotechnology Research Institute (Beijing, China). Influenza virus FM1 Strain was provided by ABSL-2 laboratory, Institute of traditional Chinese medicine, Chinese Academy of Sciences (Beijing, China). Antibodies against MyD88 (#4283), TLR4 (#14358) were obtained from Cell Signaling (Beverly, MA, USA), and antibody against MD2 (#24182) was obtained from Abcam (Cambridge, MA, England). Ribavirin (20160308) was purchased from Solarbio (Beijing, China). Ceftriaxone sodium Injection was purchased from ReYoung Pharmaceutical Co., Ltd (Shandong, China). IL-1β, IL-6, and TNF-α ELISA kits were obtained from Neobioscience (Shenzhen, China). MPO kit (A044-1-1) was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Physiological saline for injection (L219012211) was purchased from Sichuan Kelun Pharmaceutical Co., Ltd. (Chengdu, China).

Animals The study was approved by the Ethics Committee on Laboratory Animal Management of Guangxi University of Chinese Medicine (Approval Document No. SYXX-GUI-2019-0001). All animals received humane care according to the Local Guide for the Care and Use of Laboratory Animals of Guangxi University of Chinese Medicine. Healthy BALB/c mice (male and female, 6–8 weeks-old and weighing 18–22 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and acclimated for 3 days (animal license #: SCXK 2016–0006). All animals were housed under standard specific pathogen-free (SPF) conditions and given free access to food and water with a controlled temperature (25°C) and humidity (50%).

Preparation of anemoside B4 The dried roots of *Pulsatilla chinensis* (Bunge) Regel (10 kg) were powered into 100 mesh, which were further extracted by 70% ethanol to obtain liquid extract after removing the ethanol. By adding proper hot water, the extract was sequentially extracted with petroleum ether, dichloromethane, ethyl acetate, and n-butyl alcohol to get 24.2 g, 102.5 g, 34.2 g, and 685.2 g extract, respectively. The n-butyl alcohol (685.2 g) extract was further separated on a column packed with macroporous adsorption resins by gradient eluting with ethanol and water (100:0, 30:70, 60:40, 90:10) to yield four fractions: Fr. 1-Fr. 4. Fr. 3 (180.2 g) was further separated by using medium pressure liquid chromatography (MPLC) with ODS column first. Then Sephadex LH-20 gel column eluted with MeOH and semi-preparative HPLC with C18 column at a flow rate of 2
mL/min eluted with MeOH (60%) were employed for further purification to yield anemoside B4 (42.2 g). The purity of anemoside B4 was investigated by HPLC assay.

Klebsiella pneumoniae-induced bacterial pneumonia of mice All the male mice were divided randomly into six groups (n = 20 per group): control group, model group, anemoside B4-treated group (2.5, 5, 10 mg/kg) and ceftiraxone sodium-treated group (200 mg/kg). In addition to the control group, the other five groups were administrated with Klebsiella pneumoniae (1.04×10^9 CFU/mL, 50 μL/per mouse) by non-invasive intratracheal (i.t.) instillation into lung of mice. Mice were treated with anemoside B4 (i.v.) at the point of time 0, 3, 24, 48, 72 h or ceftiraxone sodium (i.v.) at the point of time 0 h. 72 hours after Klebsiella pneumoniae treatment, all experimental mice were sacrificed by dislocation. Blood samples were collected for measurement of levels of WBC, NEU, and pro-inflammatory cytokines. The parts of lung samples were collected and kept at −80 °C for western blot assay. Bronchoalveolar lavage fluid (BALF) was also taken for pro-inflammatory cytokines.

Influenza Virus FM1-induced viral pneumonia of mice All the mice were divided randomly into six groups (n = 20 per group, half male and female): control group, model group, anemoside B4-treated group (2.5, 5, 10 mg/kg) and ribavirin-treated group (40 mg/kg). In addition to the control group, the other five groups were administrated with influenza virus FM1 (The virus stock solution was diluted 500 times with normal saline solution) by non-invasive intratracheal (i.t.) instillation into lung of mice. Each group of mice was administrated (i.v.) with anemoside B4 (2.5, 5, 10 mg/kg) or ribavirin (40 mg/kg) at the point of time 0, 24, 48, 72, and 96 h. 120 h after treatment of influenza virus FM1, all experiment mice were sacrificed by dislocation. Blood samples and BALF were collected for pro-inflammatory molecules. The other of lung samples were collected and kept at −80 °C for western blot assay.

Network Pharmacology Predicts the Mechanism of B4 in Treating pneumonia Systematic pharmacology software was used to predict the underlying targets and signal pathways of anemoside B4 in treating pneumonia. Through searching TTD and TCMSP database, the targets of anemoside B4 were determined, implying the underlying mechanisms of B4 acting on pneumonia.

Hematology analysis Blood was collected from mouse orbit. The blood sample was further processed with EDTA. White blood cell and neutrophil counts from blood were determined using an auto hematology analyzer (Mindray, Shenzhen, China).

Enzyme-linked immunosorbent assay (ELISA) The blood sample was placed at room temperature for 2 hours and then centrifuged at 3000 rpm for 20 minutes to collect supernatant. The bronchoalveolar lavage fluid (BALF) was centrifuged at 1600 rpm for 10 min at 4 °C, and the supernatant was collected. The lung tissue was homogenized by a tissue grinder (TP-24, jieling instrument manufacturing Tianjin Co., Ltd, Tianjin, China). The samples were centrifuged for 20 minutes at 3000 rpm. The supernatant was immediately stored at -80°C. The pro-inflammatory molecules IL-1β, TNF-α, and IL-6 of all the supernatants were investigated by ELISA kits following the manufacturer’s instructions.

Western Blotting Analysis Lung tissues were homogenized in RIPA buffer with 1% PMSF and 1% cocktail (Sigma-Aldrich, St. Louis, MO). The lysate was centrifuged at 15,000 rpm for 25 min at 4 °C and the supernatant was harvested. The protein concentrations were examined using a BCA protein kit (Thermofisher, Waltham, MA, USA). The denatured proteins were then separated by 10% SDS-PAGE gels and transferred to PVDF membrane (Millipore, Billerica, MA, USA). After blocking the PVDF membrane with 5% nonfat milk for 2 h, the PVDF membrane was incubated with primary antibodies (1:1000) at 4 °C overnight. After washed three times with TBST and incubated with secondary antibody (1:5000) for 2 h at room temperature, the protein band signals were detected with SuperSignal West Femto maximum sensitivity substrate (Pierce Biotechnology) in a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). GAPDH was used as a housekeeping protein.

Molecular docking stimulation The molecular docking data of B4 with TLR4-MD-2 (PDB code: 3FXI) was performed in Ledock (http://www.lephar.com). TLR4-MD-2 structures were obtained from RCSB Protein Data Bank (PDB code: 3FXI) 24.

Statistical Analysis Data are presented as means ± SD. All experiments were repeated at least three independent times. Data were normally distributed and analyzed by one-way-ANOVA by Graph Pad Prism 7
software (Microsoft, Seattle, WA, USA). A P value < 0.05 was considered to be statistically significant.

**Results**

**The identification of anemoside B4**

As shown in Fig. 1A, the chemical structure of anemoside B4 was identified as 3-O-α-L-Rhamnopyranosyl-(1→2)-α-L-arabinofuranosyl-3β,23-dihydroxy lupinane-Δ20(29)ene-28-O-α-L-Rhamnose-(1→4)β-D-glucopyranose-(1→6)β-D-glucopyranoside. The purity of anemoside B4 was over 98%, which was determined by HPLC assay (Fig. 1B).

**The target network of anemoside B4.**

A network pharmacology-based strategy was proposed to elucidate the underlying multi-target mode of action of anemoside B4 against pneumonia [25] (Fig. 2). This network consisted of 10 targets involved in inflammatory process [26, 27]. Specifically, three targets including IL-1β, IL-6, and TNF-α have been reported to be related to pneumonia, which were further validated in vivo.

**Anemoside B4 exhibits anti-inflammatory effects on KP-induced pneumonia.**

Next, we investigated the effect of anemoside B4 on pro-inflammatory cytokines in vivo. Guided by the prediction results, we explored the effects of anemoside B4 on the three cytokines. The results indicated that infection of KP caused a significant increase in the secretions of TNF-α (Fig. 3A) and IL-6 (Fig. 3B) in mouse serum. Then, the administration of B4 (from 2.5 to 10 mg/kg) reduced the production of these cytokines. In addition, the rise was observed in the TNF-α (Fig. 3C, F), IL-6 (Fig. 3D, G), IL-1β (Fig. 3E), and MPO (Fig. 3H) in the BALF and lung tissue samples collected from the KP-infected pneumonia mice, which were reversed by anemoside B4. Collectively, anemoside B4 significantly prevents KP-induced pneumonia.

**Anemoside B4 restores KP-induced imbalance of blood parameters.**

The blood counts of WBC and NEU are the commonly-use biomarkers of bacterial pneumonia clinically [15]. Direct contact of the lungs with Klebsiella pneumoniae can easily cause lung inflammation in mice. The blood counts of WBC (Fig. 4A) and NEU (Fig. 4B) in the KP group were dramatically increased compared with control group. However, anemoside B4 suppressed the aberrant elevation of WBC and NEU respectively, of which the effects similar to the positive drug ceftriaxone sodium.

**Anemoside B4 decreases FM1-induced cytokines release in serum.**

Influenza virus FM1-infected pneumonia leads to an inflammatory storm, suggesting that many pro-inflammatory cytokines like TNF-α and IL-6 released into blood and lung tissue [28-30]. In our study, FM1 was non-invasive intratracheally instilled into lung tissue of mice. Results showed that mice infected by FM1 caused a significant rise in the secretions of TNF-α (Fig. 5A, C) and IL-6 (Fig. 5B, D) in both female and male mouse serum, which was suppressed by B4. Thus, anemoside B4 exhibited a protective effect on FM1-induced pneumonia.

**Anemoside B4 decreased inflammatory response of lung tissue of mice infected by FM1.**
To assess the protective effect of anemoside B4 on lung inflammation induced by FM1 infection, the levels of TNF-α and IL-6 were examined in BALF and lung tissue. As shown in Fig. 6, the levels of TNF-α and IL-6 in BALF and lung tissue were significantly increased by FM1 infection, which was reversed by anemoside B4. Our study indicated that anemoside B4 ameliorated FM1-induced lung inflammation, of which the effects were similar to the positive drug ribavirin.

**Discussion**

Pneumonia is inflammation of the terminal airways, alveoli, and interstitial lungs, which can be caused by pathogenic microorganisms such as bacteria, viruses, fungi, and atypical pathogens [34]. Among them, bacteria and virus are the main pathogenic factors [35]. Bacterial factors including streptococcus pneumoniae, staphylococcus aureus, and *Klebsiella pneumoniae*, etc. leads to pneumonia [36]. Although antibiotics were found to effectively decrease the death induced by bacterial-induced pneumonia, yet the abuse of antibiotics leads to drug-resistant or super bacterial, which is a worldwide problem. In addition to bacterial, virus like coronavirus, influenza virus, cytomegalovirus, etc. always lead to pneumonia [37]. Specifically, COVID-19 virus-induced pneumonia has a higher mortality. So far, there are not effective drugs for the treatment of COVID-19 pneumonia. Thus, to explore an effective drug to treat with pneumonia induced by bacterial or virus is imperative and necessary.

*Pulsatilla chinensis* (Bunge) Regel, a traditional Chinese medicine, was commonly used in the treatment of a variety of infectious diseases and malignant tumors [38]. A variety of saponins with anti-inflammatory and anti-tumor effects have been isolated from the root of *Pulsatilla chinensis* (Bunge) Regel, among which anemoside B4 is the major ingredient that quantized over 4.6% in terms of 2015 edition Chinese Pharmacopoeia. As it stands now, quite few studies on the pharmacological activity of anemoside B4 were found. For example, Hu et al. found that anemoside B4 could alleviate intestinal dysfunction by reducing inflammatory reaction [39, 40], which has therapeutic effects on immune system-related diseases [41, 42]. Anemoside B4 can reduce the nephrotoxicity of cisplatin [43] and the renal damage caused by adenine [44]. However, there is no relevant report on the effect and mechanism of anemoside B4 on pulmonary inflammation. In this study, we investigated the effects of B4 on pneumonia.

Data analysis from network pharmacology shows that B4 has a potential for regulating pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Among which, TNF-α is an important pro-inflammatory cytokines in the body, which plays a vital role in various physiological responses such as the synthesis and release of inflammatory mediators, neutrophil accumulation in the lungs, and complement activation [45]. And IL-6, a key cytokine produced by activated T cells and fibroblasts, has a wide range of biological activities such as immunoregulation [46, 47]. Studies have shown that IL-6 can catalyze and amplify the inflammatory response and its expression level effectively reflects the severity of tissue cell damage, which is used as an effective indicator for clinical diagnosis of acute and chronic inflammation [48]. IL-1β is an important inflammatory factor with dual sources of peripheral and central nerve, which can induce production and release of various inflammatory factors such as IL-8 [49]. Myeloperoxidase (MPO), a hemoglobin protein that is rich in neutrophils,
can catalyze the oxidation of chloride ions to produce hypochlorous acid, kill microorganisms in phagocytic cells, and destroy various target substances [50]. It plays a key role in the body to produce and regulate inflammatory response. Hematology analysis is an effective way to detect pneumonia, especially pneumonia caused by bacterial infection [51]. In most cases, a significant increase in white blood cells and neutrophils can be observed in bacterial pneumonia [52]. Therefore, hematology counts and pro-inflammatory cytokines were selected as test indicators. In practical experiments, anemoside B4 exerted significant inhibitory effects on MPO, IL-1β, IL-6, and TNF-α. Besides, anemoside B4 decreased WBC and Neu cell counts in blood of the pneumonia mice. Therefore, anemoside B4 has a significant protective effect on KP- or FM1-infected pneumonia in vivo.

Toll-like receptor 4 (TLR4), the first identified member of TLR family, is a transmembrane protein characterized by an extracellular domain containing leucine-rich repeats (LRRs) with which the MD-2 molecule is associated [53]. After binding virus, the TIR domain of TLR4 interacts with the TIR domain of MyD88 and binds to another TIR-containing adaptor protein, MyD88 adaptor-like (MAL), leading to an inflammatory cascade effector enzyme such as the expression of TNF-α, IL-1β, and IL-6 [54]. Thus, when B4 bound to TLR4, it will prevent the virus from binding to TLR4, which may be an alternative strategy to treat FM1-induced viral pneumonia. Previous study indicated that emodin can inhibit influenza viral-induced pneumonia via the TLR4 pathway [55]. In this study, our results indicated that B4 inhibited FM1-induced expression of TLR4/MyD88/MD2 proteins. Furthermore, our docking results indicated that B4 could directly bind to TLR4 protein. Therefore, anemoside B4 suppressed the FM1 or KP-induced pneumonia via the TLR4/Myd88 pathway.

Conclusion

In summary, our study demonstrated that anemoside B4 exhibited significant protective effects on *Klebsiella pneumoniae*- or influenza virus FM1 induced pneumonia via the TLR4/Myd88 signaling pathway (Fig. 8).

Abbreviations

B4: anemoside B4; KP: Klebsiella Pneumoniae; FM1: influenza virus FM1; WBC: white blood cell; NEU: neutrophils; MPO: myeloperoxidase; IL-1β: Interleukin-1β; IL-6: Interleukin-6; TNF-α: tumor necrosis factor-α; TLR4: Toll-like receptor 4; Myd88: myeloid differentiation factor 88; MD2: Myeloid differentiation protein-2; BALF: bronchoalveolar lavage fluid.

Declarations

Ethics approval and consent to participate

The study was established according to the ethical guidelines and approved by the Ethics Committee on Laboratory Animal Management of Guangxi University of Chinese Medicine.

Consent for publication

We declare that the Publisher has the Author’s permission to publish the relevant contribution.

Availability of data and materials
Not applicable.

**Competing interests**

The authors declare no competing conflict of interests.

**Funding**

We would like to appreciate the support from the Project of Guangxi Innovation-driven Development (2019AA17002), Guangxi Key Research and Development Plan (2020AB39014), Guangxi Science and Technology Base and Talent Special Project (2018AD19034), the National Natural Science Foundation of China (NSFC, 81803807, China), and Guangxi Natural Science Foundation (2018JJB140265).

**Author contributions**

GH designed the research. HJ, RY and CX conducted the experiments. HJ and GH wrote the manuscript. RY, CY, HS, WQ, CY, HL, ZY, YS and XQ revised the manuscript. All authors have read and approved the final version of the manuscript.

**Acknowledgements**

Not applicable

**References**

[1] Mandell LA. Community-acquired pneumonia: An overview [J]. *Postgraduate medicine*, 2015, **127**(6): 607-615.

[2] Dandachi D and Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment [J]. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*, 2018, **66**(6): 957-965.

[3] Musher DM, Abers MS and Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus [J]. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 2017, **65**(10): 1736-1744.

[4] Singh V and Aneja S. Pneumonia - management in the developing world [J]. *Paediatric respiratory reviews*, 2011, **12**(1): 52-59.

[5] Cubero M, Grau I, Tubau F, *et al.* Hypervirulent Klebsiella pneumoniae clones causing bacteraemia in adults in a teaching hospital in Barcelona, Spain (2007-2013) [J]. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, 2016, **22**(2): 154-160.

[6] Wyres KL and Holt KE. Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria [J]. *Current opinion in microbiology*, 2018, **45**: 131-139.

[7] Wang Z, Yin J, Li M, *et al.* Combination of shikonin with paclitaxel overcomes multidrug resistance in human
ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation [J]. Chinese Medicine, 2019, 14(1): 7.

[8] N R-F, AJ P, R M, et al. The Central Role of Non-Structural Protein 1 (NS1) in Influenza Biology and Infection [J]. International journal of molecular sciences, 2020, 21(4).

[9] R R, A D, H M, et al. Detection methods for influenza A H1N1 virus with special reference to biosensors: a review [J]. Bioscience reports, 2020, 40(2).

[10] Fu Y-J, Yan Y-Q, Qin H-Q, et al. Effects of different principles of Traditional Chinese Medicine treatment on TLR7/NF-κB signaling pathway in influenza virus infected mice [J]. Chinese Medicine, 2018, 13(1): 42.

[11] Fu Y-J, Yan Y-Q, Zheng X, et al. Effects of Xinjiaxiangruyin on the TLR7 pathway in influenza virus-infected lungs of mice housed in a hygrothermal environment [J]. Chinese Medicine, 2019, 14(1): 39.

[12] Lin L, Yan H, Chen J, et al. Application of metabolomics in viral pneumonia treatment with traditional Chinese medicine [J]. Chinese Medicine, 2019, 14(1): 8.

[13] Wang D, Li R, Wei S, et al. Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragalus Radix extract in the treatment of liver fibrosis [J]. Chinese Medicine, 2019, 14(1): 30.

[14] Wan Y, Xu L, Liu Z, et al. Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms [J]. BMC Complementary and Alternative Medicine, 2019, 19(1): 158.

[15] Berg AS, Inchley CS, Fjaerli HO, et al. Clinical features and inflammatory markers in pediatric pneumonia: a prospective study [J]. European journal of pediatrics, 2017, 176(5): 629-638.

[16] Su S-Y and Hsieh C-L. Anti-inflammatory effects of Chinese medicinal herbs on cerebral ischemia [J]. Chinese Medicine, 2011, 6(1): 26.

[17] Yuan R, Huang L, Du L-J, et al. Dihydrrotanshinone exhibits an anti-inflammatory effect in vitro and in vivo through blocking TLR4 dimerization [J]. Pharmacological research, 2019, 142: 102-114.

[18] Pociecha E, Dziurka M, Waligorski P, et al. 24-Epibrassinolide Pre-Treatment Modifies Cold-Induced Photosynthetic Acclimation Mechanisms and Phytohormone Response of Perennial Ryegrass in Cultivar-Dependent Manner [J]. J. Plant Growth Regul., 2017, 36(3): 618-628.

[19] Zhou L, Liu Z, Wang Z, et al. Astragalus polysaccharides exerts immunomodulatory effects via TLR4-mediated MyD88-dependent signaling pathway in vitro and in vivo [J]. Scientific reports, 2017, 7: 44822-44822.

[20] Guo Q, Mao X, Zhang Y, et al. Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance [J]. Journal of Translational Medicine, 2016, 14(1): 165.

[21] Deng D, Chen Z, Jia L, et al. Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial [J]. Trials, 2019, 20(1): 817.

[22] Song Y, Shan B, Li H, et al. Safety investigation of Pulsatilla chinensis saponins from chronic metabonomic study of serum biomedical changes in oral treated rat [J]. Journal of ethnopharmacology, 2019, 235: 435-445.

[23] Kang N, Shen W, Zhang Y, et al. Anti-inflammatory and immune-modulatory properties of anemoside B4 isolated from Pulsatilla chinensis in vivo [J]. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, 64: 152934-152934.

[24] Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex [J]. Nature, 2009, 458(7242): 1191-1195.
[25] Piao C-L, Luo J-L, Jin D, et al. Utilizing network pharmacology to explore the underlying mechanism of Radix Salviae in diabetic retinopathy [J]. Chinese Medicine, 2019, 14(1): 58.

[26] J B, K Z, D F, et al. Tyk2 as a target for immune regulation in human viral/bacterial pneumonia [J]. The European respiratory journal, 2017, 50(1).

[27] X G, Z Z, W Z, et al. Nuclear translocation of HIF-1α induced by influenza A (H1N1) infection is critical to the production of proinflammatory cytokines [J]. Emerging microbes & infections, 2017, 6(5): e39.

[28] X L, G G, M L, et al. Long Noncoding RNA Lnc-MxA Inhibits Beta Interferon Transcription by Forming RNA-DNA Triples at Its Promoter [J]. Journal of virology, 2019, 93(21).

[29] S C, G L, J C, et al. Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm [J]. Frontiers in immunology, 2019, 10: 1393.

[30] S Z, N G, H Q, et al. Suppressive effects of sunitinib on a TLR activation-induced cytokine storm [J]. European journal of pharmacology, 2019, 854: 347-353.

[31] MH M, PS C, E L, et al. Bacillus S-Layer-Mediated Innate Interactions During Endophthalmitis [J]. Frontiers in immunology, 2020, 11: 215.

[32] Z Y, T W, L Z, et al. WISP1 and TLR4 on Macrophages Contribute to Ventilator-Induced Lung Injury [J]. Inflammation, 2020.

[33] X F, Y L, Y Z, et al. Ethanol extracts from Ilex pubescens promotes cerebral ischemic tolerance via modulation of TLR4-MyD88/TRIF signaling pathway in rats [J]. Journal of ethnopharmacology, 2020: 112680.

[34] Carden DL and Gibb KA. Pneumonia and lung abscess [J]. Emergency medicine clinics of North America, 1983, 1(2): 345-370.

[35] Cawcutt K and Kalil AC. Pneumonia with bacterial and viral coinfection [J]. Current opinion in critical care, 2017, 23(5): 385-390.

[36] Karnad A, Alvarez S and Berk SL. Pneumonia caused by gram-negative bacilli [J]. The American journal of medicine, 1985, 79(1A): 61-67.

[37] Zou X, Tang G, Zhao X, et al. Simultaneous virus identification and characterization of severe unexplained pneumonia cases using a metagenomics sequencing technique [J]. Science China. Life sciences, 2017, 60(3): 279-286.

[38] Y S, B S, H L, et al. Safety investigation of Pulsatilla chinensis saponins from chronic metabonomic study of serum biomedical changes in oral treated rat [J]. Journal of ethnopharmacology, 2019, 235: 435-445.

[39] Y H, X C, H D, et al. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells [J]. Immunopharmacology and immunotoxicology, 2009, 31(4): 550-555.

[40] Y H, X C, H D, et al. Pulsatilla decoction and its active ingredients inhibit secretion of NO, ET-1, TNF-alpha, and IL-1 alpha in LPS-induced rat intestinal microvascular endothelial cells [J]. Cell biochemistry and function, 2009, 27(5): 284-288.

[41] Y H, K H and X W. Role of Chinese herbal medicinal ingredients in secretion of cytokines by PCV2-induced endothelial cells [J]. Journal of immunotoxicology, 2016, 13(2): 141-147.

[42] H Y, X C, C J, et al. in VivoAntiviral and Immunoregulatory Role Against PCV2 of Chinese Herbal Medicinal Ingredients [J]. Journal of veterinary research, 2017, 61(4): 405-410.

[43] L H, Y Z, N K, et al. Anemoside B4 attenuates nephrotoxicity of cisplatin without reducing anti-tumor activity
of cisplatin [J]. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 2019, **56**: 136-146.

[44] Q G, LL H, ML W, *et al*. Anemoside B4 Protects Rat Kidney from Adenine-Induced Injury by Attenuating Inflammation and Fibrosis and Enhancing Podocin and Nephrin Expression [J]. *Evidence-based complementary and alternative medicine : eCAM*, 2019, **2019**: 8031039.

[45] Farivar AS, Mackinnon-Patterson B, Woolley S, *et al*. FR167653 reduces obliterative airway disease in rats [J]. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*, 2004, **23**(8): 985-992.

[46] T K, K N, T O, *et al*. Cancer-Associated Fibroblasts Affect Intratumoral CD8 and FoxP3 T Cells Via IL6 in the Tumor Microenvironment [J]. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 2018, **24**(19): 4820-4833.

[47] F Z, K W, K S, *et al*. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry [J]. *Nature immunology*, 2019, **20**(7): 928-942.

[48] Ghasemi H. Roles of IL-6 in Ocular Inflammation: A Review [J]. *Ocular immunology and inflammation*, 2018, **26**(1): 37-50.

[49] Opal SM and DePalo VA. Anti-inflammatory cytokines [J]. *Chest*, 2000, **117**(4): 1162-1172.

[50] Yu B, Shen Y, Qiao J, *et al*. Geniposide attenuates Staphylococcus aureus-induced pneumonia in mice by inhibiting NF-κB activation [J]. *Microbial pathogenesis*, 2017, **112**: 117-121.

[51] Huang Y, Liu A, Liang L, *et al*. Diagnostic value of blood parameters for community-acquired pneumonia [J]. *International immunopharmacology*, 2018, **64**: 10-15.

[52] Ding C-Y, Lian B-Q, Ge H-L, *et al*. Predictive factors of postoperative infection-related complications in adult patients with cerebral cavernous malformations [J]. *Scientific reports*, 2020, **10**(1): 863-863.

[53] Nakamura S, Iwanaga N, Seki M, *et al*. Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice [J]. *Infection and immunity*, 2016, **84**(7): 1986-1993.

[54] Hawn TR, Verbon A, Janer M, *et al*. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires’ disease [J]. *Proceedings of the National Academy of Sciences of the United States of America*, 2005, **102**(7): 2487-2489.

[55] Dai J-P, Wang Q-W, Su Y, *et al*. Emodin Inhibition of Influenza A Virus Replication and Influenza Viral Pneumonia via the Nrf2, TLR4, p38/JNK and NF-kappaB Pathways [J]. *Molecules (Basel, Switzerland)*, 2017, **22**(10): 1754.

---

**Figures**

A
Figure 1
Chemical structure and chromatogram of enriched anemoside B4. (A) The chemical structure of anemoside B4. (B) Chromatogram of anemoside B4.
Figure 2

The network pharmacology of targets of anemoside B4 against pneumonia.
Figure 3

Effects of B4 on pro-inflammatory cytokines. The levels of TNF-α (A, C, F), IL-6 (B, D, G), IL-1β (E), and MPO (H) levels in serum, BALF and lung tissue were determined by ELISA kits and MPO kit. Value represents mean ± SD (n = 10), # p<0.05, ### p < 0.001 vs. control group, *p < 0.05, **p < 0.01, ***p < 0.001 vs. KP group.

Figure 4

Effects of anemoside B4 on blood parameters. (A) The counts of white blood cells (WBC). (B) The counts of neutrophils (NEU). Value represents mean ± SD (n = 20), ### p < 0.001 vs. control group, *p < 0.05, **p < 0.01, ***p < 0.001 vs. KP group.
Figure 5

Effects of B4 on serum parameters of mice infected by FM1. (A) The level of TNF-α in female mice serum. (B) The
level of IL-6 in female mice serum. (C) The level of TNF-α in male mice serum. (D) The level of IL-6 in male mice serum. Value represents mean ± SD (n = 10), # p<0.05, ## p<0.01, ### p<0.001 vs. control group, *p < 0.05, **p < 0.01, ***p < 0.001 vs. FM1 group.
Effects of B4 on lung parameters with FM1 infection. The level of TNF-α (A), IL-6 (B) in female mice BALF, the level of TNF-α (C), IL-6 (D) in female mice lung tissue, the level of TNF-α (E), IL-6 (F) in male mice BALF, The level of TNF-α (G), IL-6 (H) in male mice lung tissue were determined by ELISA kits. Value represents mean ± SD (n = 5), # p<0.05, ## p<0.01, ### p< 0.001 vs. control group, *p < 0.05, **p < 0.01, ***p < 0.001 vs. FM1 group.
Effects of B4 on the TLR4/MyD88 pathway. (A-C) The protein expression of TLR4, MyD88, and MD2 were measured by western blotting. (D, E) Docking results of B4 with TLR4. The chemical structure of B4 is shown in pink. TLR4 is shown in other colors. Value represents mean ± SD (n = 5), ### p < 0.001 vs. control group, ***p < 0.001 vs. FM1 group.
Figure 8
The schematic of anemoside B4’s anti-inflammatory mechanism.